drug safety News
Most Popular drug safety Story
New death reports prompt EMA review of Gilenya
European regulators are taking a closer look at Novartis' ($NVS) multiple sclerosis pill Gilenya. After the November death of a 59-year-old patient who'd just begun Gilenya therapy, triggering an FDA Read more...
Latest Headlines
- February 3, 2012
- February 2, 2012
- January 20, 2012
- January 5, 2012
- January 4, 2012
- December 21, 2011
- December 20, 2011
- December 15, 2011
- December 9, 2011
- December 9, 2011
- December 7, 2011
- November 23, 2011
- November 16, 2011
- November 15, 2011
- November 3, 2011
- November 2, 2011
- November 1, 2011
- October 11, 2011
- September 12, 2011
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
